IXICO PLC · LSE:IXI
IXICO — FY2021 Earnings Presentation
19 slides from IXICO's earnings presentation, Dec 7, 2021

Slide 1: FY21 Results
FY21 Results 7th December 2021 Giulio Cerroni Grant Nash CEO CFO

Slide 2: Nonregulated Disclaimer
Nonregulated Disclaimer This presentation is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing which accompanies it. The information in this presentation is subject to updating, revision and amendment. The information in this presentation, which incl

Slide 3: Delivering on our Purpose
Npt aco Delivering on our Purpose

Slide 4: IXICO: A company invested in a meaningful purpose
IXICO: A company invested in a meaningful purpose To advance medicine and human health by turning medical imaging data (brain scans) into clinically meaningful information. We enable our pharmaceutical clients to gain valuable new insights to accelerate the development of new medicine in neuroscienc

Slide 5: Impact of Aduhelm: First disease modifying drug for AD
Impact of Aduhelm: First disease modifying drug for AD Jun-21 FDA approved Aduhelm for clinical 2021 FDA breakthrough therapy designations use in AD in AD • Expensive • Clinical benefit uncertain • Known side effects • Requirement for further studies & post-market surveillance • 3 ‘breakthrough ther

Slide 6: IXICO: A company building valuable partnerships
IXICO: A company building valuable partnerships Ray and Dagmar Dolby Family Fund IXICO-GAP webcast can be found at the following link: https://www.brrmedia.co.uk/broadcasts/61aa006a504d020773e7e796/ixico-ixico-and-gap-interview/ Confidential and Proprietary Information

Slide 7: FY21 Financials
Npt aco FY21 Financials

Slide 8: Revenues broadly in line with prior year deliver strong Gross profit and EBITDA margins
Revenues broadly in line with prior year deliver strong Gross profit and EBITDA margins 9.5 9.2 1.7 67 66 1.3 7.6 65 56 59 0.5 5.4 45 4.1 3.1 -0.6 -1.4 -2.1 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 ▪ Stable revenues despite COVID-19 ▪ Gross margins su

Slide 9: Order book impacted by short term challenges but better positioned for long term growth
Order book impacted by short term challenges but better positioned for long term growth 16 projects; 14 clients; 21.7 9 new clients 19.3 18.8 9.2 15.9 12.7 13.8 21.7 9.9 7.5 18.8 2016 2017 2018 2019 2020 2021 30-Sep-20 Revenues Client trial Trial wins 30-Sep-21 descopes and fx ▪ Order book growth tr

Slide 10: Order book diversified across trial phase and client numbers.
Order book diversified across trial phase and client numbers. 0.6 1.2 0.5 0.7 0.2 1.5 0.1 2.7 4.1 0.5 1.2 0.5 1.0 0.5 0.7 0.6 0.9 0.7 0.5 0.6 9.3 0.7 2.2 0.7 17.4 5.6 3.5 17.0 0.4 9.9 0.6 5.3 3.9 0.6 11.0 11.1 4.0 1.8 12.4 8.0 1.3 7.6 1.0 2.9 0.5 1.2 0.5 6.2 0.8 4.9 1.0 0.7 1.5 2.2 2.3 2.2 2.5 2.0 1

Slide 11: Balance sheet oriented to support investment whilst growing
Balance sheet oriented to support investment whilst growing 2.2 11.2 7.9 7.9 7.3 6.7 9.1 7.9 7.3 1.2 3.1 3.9 2.4 0.6 2.7 0.0 0.0 0.1 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 ▪ Technology investment of >£2.0m ▪ Investments in technology, scale and ▪ Ne

Slide 12: TrialTracker: investing for future growth
TrialTracker: investing for future growth • Next generation TrialTracker platform • Microsoft Azure cloud infrastructure Clinical interpretation: standardised expert • Partnership with radiological reads Microsoft • Scale, resilience & security and efficiency • Supports deployment of new AI Data dri

Slide 13: Shareholder value creation
Shareholder value creation 13

Slide 14: Share price: impacted by short-term client trial failures and doesn't reflect business traction
Share price: impacted by short-term client trial failures and doesn’t reflect business traction and market opportunity Descope of large PIII HD trials (£7.1m) Termination of client EV = 5*Revenues trial (£3.3m) 2nd large (£10.5m) PIII HD trial won Large (£9.1m) PIII HD trial won New CEO £5.5m Raise

Slide 15: Strengthened market position: 5 years of organic growth
Strengthened market position: 5 years of organic growth Focus on Accelerate Target early Innovate Enhance delivering scale penetration phase to grow AI process organic growth and operational of clinical trials into later clinical automation through excellence market in select phases & advanced data

Slide 16: Growth strategy; increased focus on point 5
Growth strategy; increased focus on point 5 Focus on Accelerate Target early Innovate Enhance delivering scale penetration phase to grow AI process organic growth and operational of clinical trials into later clinical automation through excellence market in select phases & data analytics selective t

Slide 17: Appendix
Npt aco Appendix

Slide 18: Leadership Team: Focussed on Growth
Leadership Team: Focussed on Growth Delivery Grant Nash Romina Oxborough (Apr ‘19) (Sep ‘21) Chief Financial Officer SVP Operations Innovation Client focused Giulio Cerroni (Feb ‘17) Chief Executive Officer Robin Wolz Chris Hamilton (Mar ‘14) (Dec ‘21) Chief Scientific Officer SVP Commercial 18

Slide 19: What we do today: Imaging in neuroscience clinical trials
What we do today: Imaging in neuroscience clinical trials $1.6Bn imaging CRO clinical trials market* Focused on neurological (CNS) conditions with high unmet clinical need Business Model: “End to end” Solution; Regulatory-compliant operating model with global reach. Proposition: Advanced AI driven i
Source: Internet Archive copy of ixico.com
More decks from IXICO PLC
Investor Day (April 2026)20 slides · Apr 1, 2026
FY2025 Earnings Presentation20 slides · Dec 9, 2025
Investor Day (October 2025)53 slides · Oct 30, 2025
H1 2025 Earnings Presentation20 slides · May 2025
FY2024 Earnings Presentation24 slides · December 2024
FY2023 Earnings Presentation35 slides · Dec 5, 2023